Communication of the meeting of Transparency Council No. 14/2026 on 7 April 2026 with resolutions

We invite you to read minutes of the meeting of Transparency Council No. 14/2026 on 7 April 2026 during which the following resolutions were adopted:

1. At its meeting on 7 April 2026, the Transparency Council adopted position No. 40/2026 on the eligibility of the healthcare service “Oncotype DX® Multigene Assay (MGA) for the prognostic and predictive assessment of the benefits of chemotherapy in patients with early-stage breast cancer (ICD-10: C50), hormone-dependent (HR+), without HER2 receptor expression (HER2-), without lymph node metastasis (N0), or with metastasis to a maximum of 1–3 lymph nodes (N1).”
2. At its meeting on 7 April 2026, the Transparency Council adopted opinion No. 42/2026 on the draft program “Health Education Program on Scoliosis Prevention for Fourth- and Sixth-Grade Students in the Opole Province for 2026–2028: Early Detection and Educational Support for Children at Risk of Developing Scoliosis”
3. At its meeting on 7 April 2026, the Transparency Council adopted opinion No. 43/2026 on the draft program “Program to Increase Access to Medical Rehabilitation Services for Residents of the Municipality of Czerwieńsk for the Years 2026–2030”
4. At its meeting on 7 April 2026, the Transparency Council adopted opinion No. 44/2026 on the inclusion of medicinal products containing the active ingredients amlodipine and valsartan in the reimbursement program for indications, dosages, or routes of administration that differ from those specified in the Summary of Product Characteristics, i.e., hypertension
5. At its meeting on 7 April 2026, the Transparency Council adopted opinion No. 45/2026 on the inclusion of medicinal products containing the active ingredients amlodipine, valsartan, and hydrochlorothiazide in the reimbursement program for indications, dosages, or routes of administration other than those specified in the Summary of Product Characteristics, i.e., hypertension.
6. At its meeting on 7 April 2026, the Transparency Council adopted opinion No. 46/2026 on the inclusion of medicinal products containing the active ingredients candesartan and hydrochlorothiazide in the reimbursement program for indications, dosages, or routes of administration that differ from those specified in the Summary of Product Characteristics, i.e., hypertension
7. At its meeting on 7 April 2026, the Transparency Council adopted opinion No. 47/2026 on the inclusion of medicinal products containing the active ingredients candesartan and amlodipine in the reimbursement program for indications, dosages, or routes of administration that differ from those specified in the Summary of Product Characteristics, i.e., hypertension
8. At its meeting on 7 April 2026, the Transparency Council adopted opinion No. 48/2026 on the inclusion of medicinal products containing the active ingredients lisinopril and amlodipine in the reimbursement program for indications, dosages, or routes of administration that differ from those specified in the Summary of Product Characteristics, i.e., hypertension
9. At its meeting on 7 April 2026, the Transparency Council adopted opinion No. 49/2026 on the inclusion of medicinal products containing the active ingredients lisinopril and hydrochlorothiazide in the reimbursement program for indications, dosages, or routes of administration that differ from those specified in the Summary of Product Characteristics, i.e., hypertension
10. At its meeting on 7 April 2026, the Transparency Council adopted opinion No. 50/2026 on the inclusion of medicinal products containing the active ingredients losartan and amlodipine in the reimbursement program for indications, dosages, or routes of administration that differ from those specified in the Summary of Product Characteristics, i.e., hypertension
11. At its meeting on 7 April 2026, the Transparency Council adopted opinion No. 51/2026 on the inclusion of medicinal products containing the active ingredients losartan and hydrochlorothiazide in the reimbursement program for indications, dosages, or routes of administration that differ from those specified in the Summary of Product Characteristics, i.e., hypertension
12. At its meeting on 7 April 2026, the Transparency Council adopted opinion No. 52/2026 on the inclusion of medicinal products containing the active ingredients perindopril and amlodipine in the reimbursement program for indications, dosages, or routes of administration that differ from those specified in the Summary of Product Characteristics, i.e., hypertension
13. At its meeting on 7 April 2026, the Transparency Council adopted opinion No. 53/2026 on the inclusion of medicinal products containing the active ingredients perindopril and indapamide in the reimbursement program for indications, dosages, or routes of administration that differ from those specified in the Summary of Product Characteristics, i.e., hypertension
14. At its meeting on 7 April 2026, the Transparency Council adopted opinion No. 54/2026 on the inclusion of medicinal products containing the active ingredients ramipril and amlodipine in the reimbursement program for indications, dosages, or routes of administration that differ from those specified in the Summary of Product Characteristics, i.e., hypertension
15. At its meeting on 7 April 2026, the Transparency Council adopted opinion No. 55/2026 on the inclusion of medicinal products containing the active ingredients ramipril and felodipine in the reimbursement program for indications, dosages, or routes of administration that differ from those specified in the Summary of Product Characteristics, i.e., hypertension
16. At its meeting on 7 April 2026, the Transparency Council adopted opinion No. 56/2026 on the inclusion of medicinal products containing the active ingredients ramipril and hydrochlorothiazide in the reimbursement program for indications, dosages, or routes of administration that differ from those specified in the Summary of Product Characteristics, i.e., hypertension
17. At its meeting on 7 April 2026, the Transparency Council adopted opinion No. 57/2026 on the inclusion of medicinal products containing the active ingredients telmisartan and amlodipine in the reimbursement program for indications, dosages, or routes of administration that differ from those specified in the Summary of Product Characteristics, i.e., hypertension
18. At its meeting on 7 April 2026, the Transparency Council adopted opinion No. 58/2026 on the inclusion of medicinal products containing the active ingredients telmisartan and hydrochlorothiazide in the reimbursement program for indications, dosages, or routes of administration that differ from those specified in the Summary of Product Characteristics, i.e., hypertension
19. At its meeting on 7 April 2026, the Transparency Council adopted opinion No. 59/2026 on the inclusion of medicinal products containing the active ingredients telmisartan and indapamide in the reimbursement program for indications, dosages, or routes of administration that differ from those specified in the Summary of Product Characteristics, i.e., hypertension
20. At its meeting on 7 April 2026, the Transparency Council adopted opinion No. 60/2026 on the inclusion of medicinal products containing the active ingredients valsartan and hydrochlorothiazide in the reimbursement program for indications, dosages, or routes of administration that differ from those specified in the Summary of Product Characteristics, i.e., hypertension

Transparency Council meeting protocol >>